2. MAPK/ERK Pathway Immunology/Inflammation Apoptosis
  3. JNK p38 MAPK Interleukin Related TNF Receptor
  4. JNK2/MKK7 PPI-IN-1

JNK2/MKK7 PPI-IN-1 is an orally active JNK2 inhibitor with an IC50 of 0.99 μM and a Kd of 81.6 μM. JNK2/MKK7 PPI-IN-1 inhibits JNK2 kinase activity, disrupts JNK2-MKK7 protein-protein interaction, and reduces c-Jun phosphorylation. JNK2/MKK7 PPI-IN-1 inhibits LPS-induced overexpression of inflammatory cytokines IL-6 and TNF-α. JNK2/MKK7 PPI-IN-1 can be used for the research of acute lung injury.

For research use only. We do not sell to patients.

JNK2/MKK7 PPI-IN-1

JNK2/MKK7 PPI-IN-1 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

JNK2/MKK7 PPI-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

JNK2/MKK7 PPI-IN-1 is an orally active JNK2 inhibitor with an IC50 of 0.99 μM and a Kd of 81.6 μM. JNK2/MKK7 PPI-IN-1 inhibits JNK2 kinase activity, disrupts JNK2-MKK7 protein-protein interaction, and reduces c-Jun phosphorylation. JNK2/MKK7 PPI-IN-1 inhibits LPS-induced overexpression of inflammatory cytokines IL-6 and TNF-α. JNK2/MKK7 PPI-IN-1 can be used for the research of acute lung injury[1].

IC50 & Target[1]

JNK2

0.99 μM (IC50)

JNK2

81.6 μM (Kd)

IL-6

 

In Vitro

JNK2/MKK7 PPI-IN-1 (6I) (0.08-10 μM; 24 h) inhibits LPS-induced IL-6 secretion in J774A.1 macrophages (IC50 = 2.78 μM) and THP-1 macrophages (IC50 = 0.14 μM), and suppresses TNF-α secretion in J774A.1 macrophages (IC50 = 0.55 μM)[1].
JNK2/MKK7 PPI-IN-1 (5, 10 μM; 24 h) suppresses LPS-induced IL-6 and TNF-α mRNA expression in RAW 264.7 macrophages[1].
JNK2/MKK7 PPI-IN-1 (0.125-4 μM) inhibits JNK2 kinase activity with an IC50 of 0.99 μM[1].
JNK2/MKK7 PPI-IN-1 (20-60 μM) disrupts the interaction between JNK2 and MKK7, as confirmed by co-immunoprecipitation assays[1].
JNK2/MKK7 PPI-IN-1 (6.25-200 μM) binds to JNK2 with a Kd of 81.6 μM, measured by surface plasmon resonance (SPR)[1].
JNK2/MKK7 PPI-IN-1 (10 μM; 1 h) stabilizes JNK2 protein against thermal denaturation in intact RAW 264.7 cells[1].
JNK2/MKK7 PPI-IN-1 (0.2-5 μM; 24 h) inhibits LPS-induced phosphorylation of c-Jun, p38, and p65, and preserves IκBα protein level in RAW 264.7 macrophages[1].
JNK2/MKK7 PPI-IN-1 (5 μM; 24 h) suppresses LPS-induced nuclear translocation of c-Jun in RAW 264.7 macrophages, visualized by immunofluorescence staining[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

JNK2/MKK7 PPI-IN-1 Related Antibodies

ELISA Assay[1]

Cell Line: RAW 264.7 macrophages
Concentration: 10 μM (pre-incubation for LPS-induced IL-6 inhibition); 0.08, 0.4, 2, 10 μM (dose-response testing)
Incubation Time: 0.5 h (pre-incubation); 24 h (LPS stimulation)
Result: Inhibited LPS-induced IL-6 production by 86.86% at 10 μM, with an IC50 of 0.32 μM in a dose-dependent manner.

Real Time qPCR[1]

Cell Line: RAW 264.7 macrophages
Concentration: 5, 10 μM
Incubation Time: 3 h (pre-incubation); 6 h (LPS stimulation)
Result: Significantly suppressed LPS-induced elevations in IL-6 and TNF-α mRNA levels in a dose-dependent manner.

Immunofluorescence[1]

Cell Line: RAW 264.7 macrophages
Concentration: 10 μM
Incubation Time: 2 h (pre-incubation); 30 min (LPS stimulation)
Result: Significantly suppressed LPS-induced nuclear translocation of c-Jun.

Western Blot Analysis[1]

Cell Line: RAW 264.7 macrophages
Concentration: 0.2 μM, 1 μM, 5 μM
Incubation Time: 2 h (pre-incubation); 30 min (LPS stimulation)
Result: Inhibits LPS-induced phosphorylation of c-Jun, p38, and p65; preserves IκBα protein level compared to LPS-treated group.
Parmacokinetics
Species Dose Route T1/2 Tmax Cmax AUC0-t Bioavailability
Rat[1] 1 mg/kg i.v. 4.516 h 0.083 h 3752.137 ng/mL 6202.702 ng·h/mL 70.3 %
Rat[1] 4 mg/kg p.o. 3.505 h 3.333 h 1854.57 ng/mL 17433.294 ng·h/mL - %
In Vivo

JNK2/MKK7 PPI-IN-1 (20 mg/kg; p.o.; three doses at 12-hour intervals) significantly reduces pulmonary edema, alveolar permeability, and inflammatory cytokine production in LPS (HY-D1056)-induced ALI in mice, significantly alleviates pulmonary edema, alveolar damage, and inflammatory cytokine production in CLP-induced ALI in mice[1].
JNK2/MKK7 PPI-IN-1 (500 mg/kg; p.o.; single dose) shows favorable acute safety in male C57BL/6 mice, with no mortality, organ damage, or persistent body weight loss[1].
JNK2/MKK7 PPI-IN-1 (100 mg/kg; p.o.; daily; 14 days) shows favorable subacute safety in male C57BL/6 mice, with no mortality, organ damage, or significant liver enzyme elevation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (male, 18-22 g, LPS-induced ALI)[1]
Dosage: 20 mg/kg
Administration: p.o.; three doses at 12-hour intervals
Result: Significantly attenuated LPS-induced pulmonary edema (reduced lung wet/dry weight ratio).
Decreased protein concentration and total cell counts in bronchoalveolar lavage fluid (BALF).
Reduced IL-6 levels in both serum and BALF.
Alleviated LPS-induced splenomegaly.
Reduced lung tissue damage, neutrophil influx, and macrophage infiltration compared to LPS-only controls.
Reduced splenic histopathological changes compared to LPS-only controls.
Animal Model: C57BL/6 (male, 18-22 g, CLP-induced sepsis ALI)[1]
Dosage: 20 mg/kg
Administration: p.o.; three doses at 12-hour intervals
Result: Significantly reduced CLP-induced pulmonary edema (lower lung wet/dry weight ratio compared to CLP-only controls).
Decreased protein concentration and total cell counts in BALF.
Reduced IL-6 and IL-1β levels in BALF.
Ameliorated CLP-induced splenomegaly.
Reduced lung tissue injury, inflammatory cell infiltration, and alveolar septal thickening compared to CLP-only controls.
Reduced splenic white pulp fusion compared to CLP-only controls.
Animal Model: C57BL/6 (male, 18-22 g)[1]
Dosage: 500 mg/kg
Administration: p.o.; single dose
Result: Observed no mortality or abnormal behaviors.
Showed an initial slight decrease in body weight, followed by gradual recovery to levels comparable to controls.
Showed no significant organ damage in heart, liver, spleen, lung, or kidney tissues via histopathological analysis.
Animal Model: C57BL/6 (male, 18-22 g)[1]
Dosage: 100 mg/kg
Administration: p.o.; daily; 14 days
Result: Observed no mortality or abnormal behaviors.
Showed a non-significant decrease in body weight that recovered by day 6.
Showed no significant differences in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels compared to controls.
Showed no significant organ damage in heart, liver, spleen, lung, or kidney tissues via histopathological analysis.
Molecular Weight

459.49

Formula

C26H25N3O5
SMILES

O=C(NC1=CC=C(OC2=CC=NC3=CC(OC(C)C)=C(C=C32)OC)C=C1)C4=CN(C(C=C4)=O)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

JNK2/MKK7 PPI-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

JNK2/MKK7 PPI-IN-1JNKp38 MAPKInterleukin RelatedTNF Receptorc-Jun N-terminal kinaseILTumor Necrosis Factor ReceptorTNFRRAW 264.7 macrophagesJNK2acute lung injuryIL-6TNF-αc-JunTHP-1 macrophageshERG channelsMKK7J774A.1 macrophagesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
JNK2/MKK7 PPI-IN-1
Cat. No.:
HY-181812
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.